Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 11/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328615 | 0.91 | C5AR1 (0.38) | C5AR1OPRM1PRCPOPRK1DRD2 | |
| SCHEMBL1329867 | 0.91 | C5AR1 (0.38) | C5AR1OPRM1PRCPOPRK1DRD2 | |
| SCHEMBL1328532 | 0.90 | C5AR1 (0.44) | C5AR1 | |
| SCHEMBL1329621 | 0.89 | C5AR1 (0.39) | C5AR1OPRM1PRCPOPRK1 | |
| SCHEMBL1328166 | 0.89 | C5AR1 (0.38) | C5AR1OPRM1RAB9A | |
| SCHEMBL1327523 | 0.89 | C5AR1 (0.39) | C5AR1OPRM1PRCPOPRK1DRD2 | |
| SCHEMBL1327861 | 0.89 | OPRM1 (0.37) | C5AR1OPRM1PRCPOPRK1DRD2 | |
| SCHEMBL1327123 | 0.85 | C5AR1 (0.39) | C5AR1OPRM1PRCPDRD2 | |
| SCHEMBL1329447 | 0.84 | C5AR1 (0.39) | C5AR1PRCPDRD2DRD1 | |
| SCHEMBL1328590 | 0.82 | C5AR1 (0.39) | C5AR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885OPRM1 674/4885RAB9A 736/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885OPRM1 674/4885RAB9A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.